(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.94%.
Corbus Pharmaceuticals Holdings's earnings in 2026 is -$84,528,000.On average, 12 Wall Street analysts forecast CRBP's earnings for 2026 to be -$87,688,348, with the lowest CRBP earnings forecast at -$103,496,263, and the highest CRBP earnings forecast at -$64,393,352. On average, 11 Wall Street analysts forecast CRBP's earnings for 2027 to be -$97,243,132, with the lowest CRBP earnings forecast at -$133,637,280, and the highest CRBP earnings forecast at -$49,608,171.
In 2028, CRBP is forecast to generate -$104,654,250 in earnings, with the lowest earnings forecast at -$135,997,721 and the highest earnings forecast at -$59,724,347.